We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
You may need to tell DVLA if you have diabetes, depending on the treatment you're getting
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Increase in suspected adverse event reports following use of Caninsulin 40 IU/ml Suspension for Injection.
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
This study reported high prevalence, especially of undiagnosed cases amongst adults, most have uncontrolled blood sugar levels
Information for patients, healthcare professionals and developers of new medicines
The new presentation of Mounjaro gives four doses for once-a-week treatment over a month.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).